Skip to content
Scott Ganz /

The Oxford Vaccine’s True Efficacy Remains Uncertain

The preliminary results provided reason for optimism, but left many questions unanswered.
The Oxford Vaccine’s True Efficacy Remains Uncertain

The vaccine candidate sponsored by the University of Oxford and AstraZeneca has shown promise in preventing COVID-19 in Phase III clinical trials, but the evidence is not yet convincing enough to put it in the same category as competitors from Pfizer-BioNTech and Moderna. Consequently, it is likely that the Food and Drug Administration (FDA) will insist on more and better data before granting regulatory approval.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Scott Ganz is a research fellow in economic policy at the American Enterprise Institute. He is also an associate teaching professor of strategy at the McDonough School of Business at Georgetown University. From 2009 to 2011, he was special assistant to the vice chairman on the Financial Crisis Inquiry Commission.

More We Think You’d Like

Loading